Clinical Significance of Prothrombin Time in Cholangiocarcinoma Patients with Surgeries

Table 1

Demographics and clinical characteristics of patients with cholangiocarcinoma.

Variable	Mean ± SD (Frequency)	Range
Gender (M/F)	48/38	-
Age	62.32±11.17	35-96
PLT, 10^9/L	208.81±72.77	48.6-414.0
PDW, fL	17.17±8.58	10.6-53.3
MPV, fL	11.70±1.71	6.6-19.1
LYM, 10^9/L	1.24±0.50	0.28-3.01
NEU, 10^9/L	5.63±2.68	1.1-14.04
PLR	189.61±106.14	58.93-883.93
NLR	5.36±3.84	1-19.65
APTT,s	28.50±6.31	19.0-59.8
PT,s	11.53±1.48	9.3±17.9
INR	0.996±0.124	0.8-1.52
FIB, g/L	3.94±1.32	1.2-7.9
TT, s	18.35±2.42	15.2-34.1
DD, ug/mL	1.14±1.79	0.08-12.96
ALB, g/L	36.17±6.15	20-56
CRP, mg/L	38±47.18	1-240
GPS (0/1-2)	19/67	-
CA199, U/ml	1108.09±6780.71	0.6-59575
CA125, U/ml	36.50±47.98	3.5- 246.1
CEA, ng/ml	4.97±6.78	0.2-44.83
Differentiation (Middle-High/Low)	56/29	-
Lymph (+)/(-)	39/47	-
Nerve (+)/(-)	60/26	-
Stage (I-II/III-IVA)	62/24	-
Recurrence (Y/N)	65/21	-
Die (Y/N)	57/29	-
OS, months	20.82±18.97	2.8-95.8
RFS, months	15.35±19.14	1.0-95.8

PLT, platelet count, PDW, platelet distribution width, MPV, mean platelet volume, LYM, lymphocyte count NEU, neutrophil count, PLR, platelet-lymphocyte ratio, NLR, neutrophil-lymphocyte ratio, ALB, albumin, CRP, C-reactive protein, GPS, Glasgow Prognostic Score, APTT, activated partial thromboplastin time, PT, prothrombin time, INR, international normalized ratio, FIB, fibrinogen, TT, thrombin time, DD: D-dimer, Lymph: lymph node metastasis, and Nerve, nerve invasion. OS, overall survival and RFS, recurrence-free survival.